Denali Therapeutics (DNLI) Enterprise Value: 2017-2025
Historic Enterprise Value for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to $1.3 billion.
- Denali Therapeutics' Enterprise Value fell 61.76% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 373.23%. This contributed to the annual value of $1.9 billion for FY2024, which is 3.24% down from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Enterprise Value is $1.3 billion, which was up 12.19% from $1.1 billion recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Enterprise Value registered a high of $8.2 billion during Q2 2021, and its lowest value of $1.1 billion during Q2 2025.
- Moreover, its 3-year median value for Enterprise Value was $1.9 billion (2024), whereas its average is $2.0 billion.
- As far as peak fluctuations go, Denali Therapeutics' Enterprise Value skyrocketed by 192.71% in 2021, and later slumped by 68.90% in 2022.
- Denali Therapeutics' Enterprise Value (Quarterly) stood at $4.6 billion in 2021, then tumbled by 49.18% to $2.3 billion in 2022, then decreased by 17.05% to $1.9 billion in 2023, then decreased by 3.24% to $1.9 billion in 2024, then crashed by 61.76% to $1.3 billion in 2025.
- Its Enterprise Value was $1.3 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.2 billion in Q1 2025.